Value of the Serum Procalcitonin Level to Guide Antimicrobial Therapy for Patients with Ventilator-Associated Pneumonia

ABSTRACT

Procalcitonin's contribution to the diagnosis of nosocomial infection, particularly ventilator-associated pneumonia (VAP), is poor: its levels in patients with microbiologically documented VAP the day infection is diagnosed range from normal to extremely high. Moreover, the results of four studies showed that, despite relatively good specificity, this marker had low sensitivity for the diagnosis of VAP. However, because procalcitonin is well associated with outcome, its kinetics during antimicrobial therapy can be used to customize that treatment duration. Two recent studies showed that a procalcitonin-based strategy (recommending that treating physicians stop antibiotics when the procalcitonin concentration was <0.5 ng/mL, or had decreased by ≥80%) led to less antibiotic consumption by VAP patients, compared with a conventional strategy, with no adverse outcome. Accordingly, for VAP patients, procalcitonin may be used to stop antibiotics as early as day 3 after their initiation, if its concentration is <0.5 ng/mL or has decreased by ≥80%, compared with the first peak concentration.

KEYWORDS

Procalcitonin - ventilator-associated pneumonia - nosocomial infection - antibiotics

REFERENCES

• 1 American Thoracic Society . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 (4) 388-416
• 2 Chastre J, Fagon J Y. Ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2002;  165 (7) 867-903
• 3 Chastre J, Wolff M, Fagon J Y PneumA Trial Group et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 (19) 2588-2598
• 4 el Moussaoui R, de Borgie C A, van den Broek P et al.. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.  BMJ. 2006;  332 (7554) 1355
• 5 Müller B, Becker K L. Procalcitonin: how a hormone became a marker and mediator of sepsis.  Swiss Med Wkly. 2001;  131 (41-42) 595-602
• 6 Müller B, White J C, Nylén E S, Snider R H, Becker K L, Habener J F. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis.  J Clin Endocrinol Metab. 2001;  86 (1) 396-404
• 7 Chastre J, Luyt C E, Trouillet J L, Combes A. New diagnostic and prognostic markers of ventilator-associated pneumonia.  Curr Opin Crit Care. 2006;  12 (5) 446-451
• 8 Nylen E S, Whang K T, Snider Jr R H, Steinwald P M, White J C, Becker K L. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis.  Crit Care Med. 1998;  26 (6) 1001-1006
• 9 Wagner K E, Martinez J M, Vath S D et al.. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs.  Crit Care Med. 2002;  30 (10) 2313-2321
• 10 Becker K L, Nylén E S, Snider R H, Müller B, White J C. Immunoneutralization of procalcitonin as therapy of sepsis.  J Endotoxin Res. 2003;  9 (6) 367-374
• 11 Christ-Crain M, Müller B. Procalcitonin in bacterial infections—hype, hope, more or less?.  Swiss Med Wkly. 2005;  135 (31-32) 451-460
• 12 Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy.  Expert Rev Anti Infect Ther. 2010;  8 (5) 575-587
• 13 Blasi F, Stolz D, Piffer F. Biomarkers in lower respiratory tract infections.  Pulm Pharmacol Ther. 2010;  23 (6) 501-507
• 14 Christ-Crain M, Jaccard-Stolz D, Bingisser R et al.. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.  Lancet. 2004;  363 (9409) 600-607
• 15 Christ-Crain M, Stolz D, Bingisser R et al.. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.  Am J Respir Crit Care Med. 2006;  174 (1) 84-93
• 16 Briel M, Schuetz P, Mueller B et al.. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.  Arch Intern Med. 2008;  168 (18) 2000-2007; discussion 2007–2008
• 17 Schuetz P, Christ-Crain M, Thomann R ProHOSP Study Group et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.  JAMA. 2009;  302 (10) 1059-1066
• 18 Stolz D, Christ-Crain M, Bingisser R et al.. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.  Chest. 2007;  131 (1) 9-19
• 19 Gibot S, Cravoisy A, Levy B, Bene M C, Faure G, Bollaert P E. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia.  N Engl J Med. 2004;  350 (5) 451-458
• 20 Luyt C E, Guérin V, Combes A et al.. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 (1) 48-53
• 21 Seligman R, Meisner M, Lisboa T C et al.. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia.  Crit Care. 2006;  10 (5) R125
• 22 Duflo F, Debon R, Monneret G, Bienvenu J, Chassard D, Allaouchiche B. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia.  Anesthesiology. 2002;  96 (1) 74-79
• 23 Luyt C E, Combes A, Reynaud C et al.. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia.  Intensive Care Med. 2008;  34 (8) 1434-1440
• 24 Charles P E, Kus E, Aho S et al.. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report.  BMC Infect Dis. 2009;  9 49
• 25 Jung B, Embriaco N, Roux F et al.. Microbiological data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score.  Intensive Care Med. 2010;  36 (5) 790-798
• 26 Ramirez P, Garcia M A, Ferrer M et al.. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia.  Eur Respir J. 2008;  31 (2) 356-362
• 27 Brunkhorst F M, Al-Nawas B, Krummenauer F, Forycki Z F, Shah P M. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia.  Clin Microbiol Infect. 2002;  8 (2) 93-100
• 28 Meisner M. Procalcitonin: experience with a new diagnostic tool for bacterial infection and systemic inflammation [in German].  J Lab Med. 1999;  23 263-272
• 29 Linssen C F, Bekers O, Drent M, Jacobs J A. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia.  Ann Clin Biochem. 2008;  45 (Pt 3) 293-298
• 30 Bouadma L, Luyt C E, Tubach F PRORATA Trial Group et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.  Lancet. 2010;  375 (9713) 463-474
• 31 Tang B M, Eslick G D, Craig J C, McLean A S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis.  Lancet Infect Dis. 2007;  7 (3) 210-217
• 32 Kristoffersen K B, Søgaard O S, Wejse C et al.. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial.  Clin Microbiol Infect. 2009;  15 (5) 481-487
• 33 Nobre V, Harbarth S, Graf J D, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.  Am J Respir Crit Care Med. 2008;  177 (5) 498-505
• 34 Stolz D, Smyrnios N, Eggimann P et al.. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study.  Eur Respir J. 2009;  34 (6) 1364-1375
• 35 Schroeder S, Hochreiter M, Koehler T et al.. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study.  Langenbecks Arch Surg. 2009;  394 (2) 221-226
• 36 Svoboda P, Kantorová I, Scheer P, Radvanova J, Radvan M. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?.  Hepatogastroenterology. 2007;  54 (74) 359-363
• 37 Hochreiter M, Köhler T, Schweiger A M et al.. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial.  Crit Care. 2009;  13 (3) R83
• 38 Kopterides P, Siempos I I, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials.  Crit Care Med. 2010;  38 (11) 2229-2241